Fausto A. Rios Olais

Culichi 🇲🇽 / Hematology & IM @incmnszmx / Leukemia

[𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM @nihardesai89]

Aza + venetoclax

[Fausto A. Rios Olais @faustor]

Posters 6273 & 5109 tonight @ #ASH25 @ASH_hematology

[Bloodman @Bloodman]

ASH Plenary - IV Iron safe in infections! https://t.co/95lVMroo34

[Fausto A. Rios Olais @faustor]

Should we reexpose patients after asparaginase associated pancreatitis? 🤔🤔🤔

[Mostafa Faisal @MostafaFaisal14]

👩‍⚕️ 7,640 ALL kids:
AAP risk ↑ with age & IR/HR (2.2% LR vs 5.8% IR/HR)
🔄 Early AAP rechallenge ↑ 5y EFS (80.1% vs 60.2%)
📉 No rechallenge + high MRD ↓ survival
Early IR/HR no rechallenge: EFS 53.3%

[Fausto A. Rios Olais @faustor]

📊 How many patients with lymphoma or myeloma in the US actually benefit from bispecific antibodies?

In our @BloodAdvances letter, we estimate eligibility and response under current FDA labels—and why real-world benefit may be limited.

@THilalMD

https://t.co/RqjOpwIjzh

[Sergio Rodríguez-Rodriguez, MD, MSc. 🇲🇽 @SergioRdzRdz]

🎯 Bottom line:
Allo-HSCT offers curative potential in MDS/MPN overlap neoplasms.
PTCy (± ATG) appears to improve survival outcomes without added relapse risk.
👉 Further multicenter studies needed.
📖 Full study: https://t.co/zjZCaeTGm6
#HemeTwitter #AlloHSCT #GVHD

[NEJM @NEJM]

Combined treatment with a tyrosine kinase inhibitor and blinatumomab has converted Ph-positive ALL, once the most deadly hematologic cancer, to a disease with long-term survival of 75 to 80%.

Read the full review “Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress” by Robin Foà, MD, from @sapienzaroma: https://t.co/tox4rTRrr3

[ALL Hub @ALL_Hub_]

📝 A retrospective analysis published in Leukemia & Lymphoma found that the median OS was not reached in patients with Ph+ B-ALL receiving rituximab vs 14 months in those who did not.

More news: https://t.co/0uF3bb06t5

#allsm #leusm #MedNews #MedEd

[Roberta Demichelis @RobertaDemiche3]

Thanks to all the professors and attendees who joined us at this first hematology congress at @incmnszmx @DrWendyStock @garciamanero @PratzKW @AlejandroLazo2 @RubenNiesvizky @GCC_Cortes @EnriqueSoto8 @CarmeloGurnari @Meyaix @patsnavarrete @VazyurVasquez @rajuan_27

[Fausto A. Rios Olais @faustor]

@FernandoGLMD Esoooooo 🥹🥹🥹🙌🏻🙌🏻🙌🏻

[Fausto A. Rios Olais @faustor]

📢 Body composition in adult ALL

📊 In our study published at @ESPENorg, CT-assessed muscle mass & adiposity (visceral & subcutaneous) were linked to worse survival & more infections.

https://t.co/OQViWUy960

@RobertaDemiche3 @FernandoGLMD @analymorac @JessicaZaS

[Fausto A. Rios Olais @faustor]

@mariempf @incmnszmx Felicidades Mariemcita!!!

[Roberta Demichelis @RobertaDemiche3]

🔬 ¡Lanzamos un nuevo proyecto de leucemia linfoblástica aguda (LLA)! 🌎💉
Si tratas adultos con LLA en LATAM, te invitamos a participar completando nuestro formulario.
🔗 https://t.co/UC5cfv2E4y
Tu aporte será clave para mejorar la atención de LLA en la región.

[Fausto A. Rios Olais @faustor]

@carmencrios Ando igual 🆘🆘🆘🆘

[INCMNSZ @incmnszmx]

El INCMNSZ felicita a la Dra. María Roberta Demichelis Gómez por su nombramiento como Jefa del Departamento de Hematología y Oncología.

[Jessica Zalapa @JessicaZaS]

1/ 📢 Let’s dive into a crucial topic in #Hematology: How do adult regimens compare with pediatric-inspired regimens (PIRs) for Philadelphia-negative ALL? Our study from Mexico offers some insights #ALL

@RobertaDemiche3 @faustor @rajuan_27 @analymorac

https://t.co/b8ydOWFbg5

[Fausto A. Rios Olais @faustor]

7/ Conclusions
🔹 Rituximab + TKIs may improve early responses and enhance survival in CD20+ Ph+ ALL without added toxicity.
🔹 These findings are critical for LMICs, where access to newer therapies is limited.
🔹 Future prospective trials are essential to confirm these results.

[Fausto A. Rios Olais @faustor]

4/ Results: Molecular Response

Patients receiving rituximab achieved significantly higher 3-month MR4 rates:
🔹 Rituximab: 84%
🔹 No rituximab: 59%
OR: 3.66 (p = .027)

3-month MR4 is critical, as it is linked to improved survival and lower relapse rates in some Ph+ ALL trials.

[Fausto A. Rios Olais @faustor]

6/ Dose-dependent effects

✔️ Patients receiving >4 doses of rituximab had significantly better OS.
•Median OS: Not reached (>4 doses) vs. 10 months (≤4 doses).
•HR for mortality: 0.27 (p = .034).

This aligns with prior data emphasizing the importance of adequate dosing.